← Back to Clinical Trials
Recruiting NCT06528938

NCT06528938 Comparing the Efficacy of Accelerated vs. Standard fMRI-guided iTBS in Treating Adolescents Depression

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06528938
Status Recruiting
Phase
Sponsor The Royal Ottawa Mental Health Centre
Condition Depression
Study Type INTERVENTIONAL
Enrollment 10 participants
Start Date 2024-08-01
Primary Completion 2026-08-01

Trial Parameters

Condition Depression
Sponsor The Royal Ottawa Mental Health Centre
Study Type INTERVENTIONAL
Phase N/A
Enrollment 10
Sex ALL
Min Age 16 Years
Max Age 19 Years
Start Date 2024-08-01
Completion 2026-08-01
Interventions
Theta Burst Stimulation

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

Repetitive transcranial magnetic stimulation (rTMS) is a Health Canada approved treatment for major depression. Theta burst stimulation (TBS), a type of rTMS, is a very promising new treatment for major depression in adults and adolescents. However, very few studies have assessed the efficacy of accelerated, three times a day TBS in comparison with standard once a day TBS in adolescents. The study aims to explore further evidence in hopes to conduct a large-scale, randomized, multisite, placebo-controlled clinical trial evaluating the effects of a functional magnetic resonance imaging (fMRI)-guided accelerated rTMS protocol vs. standard once/daily rTMS for treatment-resistant depression in adolescents.

Eligibility Criteria

Inclusion Criteria: 1. Voluntary and competent to consent. 2. Ages 16-19 years old. 3. Can speak and read English. 4. Primary and/or predominant diagnosis of major depressive episode without psychotic features in the current episode, confirmed by The Mini International Neuropsychiatric Interview for Children and Adolescents (MINI-KID). 5. Depressive symptoms have not improved after ≥ 1 adequate dose of antidepressant in the current depressive episode. 6. Moderate symptoms in the current depressive episode, indexed by a score of at least 40 on the Children's Depression Rating Scale Revised for depression (CDRS-R). 7. Are able to adhere to the treatment schedule. 8. Have stable psychotropic medications and/or psychotherapy regimen for at least four weeks before participating in the trial. Exclusion Criteria: 1. Diagnosis of bipolar I or II disorder, based on the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) criteria. 2. Current or past substance (\< 3 months)

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology